A practical, field-tested LOI framework built for pain management clinic acquisitions — covering MSO structures, DEA compliance provisions, physician retention earnouts, and payer mix protections in the $1M–$5M revenue range.
A Letter of Intent (LOI) is the critical document that converts early-stage interest into a structured, exclusive negotiation between a buyer and a pain management clinic owner. In pain management acquisitions, the LOI carries unusual weight because it must address a set of issues that simply do not exist in standard business purchases: corporate practice of medicine (CPOM) laws that may prohibit direct ownership by non-physicians, DEA registration transfer complexities, payer contract assignability, and the risk that physician departure post-close erodes the revenue base the buyer paid for. For deals in the $1M–$5M revenue range — whether structured as an asset purchase with SBA 7(a) financing, a Management Services Organization (MSO) arrangement, or a stock purchase with earnout provisions — the LOI sets the tone for every downstream negotiation. A well-crafted LOI signals that the buyer understands the regulatory environment, respects the seller's clinical legacy, and has thought through the operational continuity risks that make pain clinic acquisitions more complex than most lower middle market healthcare transactions. This guide walks through every section of an effective LOI for a pain management clinic acquisition, including realistic example language, negotiation notes, and the most common mistakes that kill deals or create expensive post-close surprises.
Find Pain Management Clinic Businesses to Acquire1. Parties and Practice Identification
Clearly identifies the buyer entity, the seller (typically the physician-owner or ownership group), and the legal entity being acquired — whether a professional corporation (PC), professional limited liability company (PLLC), or sole proprietorship operating under a DBA. For MSO structures, this section must distinguish between the physician-owned professional entity and the management services organization that will hold non-clinical assets.
Example Language
This Letter of Intent ('LOI') is entered into as of [Date] between [Buyer Entity Name], a [State] limited liability company ('Buyer'), and [Physician Name, MD], an individual, and [Practice Legal Name], a [State] professional corporation ('Seller'). Buyer proposes to acquire substantially all of the assets of the Practice, or alternatively to structure the transaction through a Management Services Organization arrangement in compliance with [State] corporate practice of medicine requirements, as further described herein.
💡 If the buyer is a non-physician (search fund operator, PE-backed MSO, or investor group), the parties section must acknowledge upfront that a CPOM-compliant structure — typically an MSO paired with a physician-owned PC — will be required in many states including California, Texas, and New York. Identify this early to prevent the seller from assuming a straightforward asset purchase is possible. If the buyer is a physician or physician group, a direct asset or stock purchase may be feasible and simpler. Confirm the state's CPOM rules with a healthcare attorney before finalizing this section.
2. Transaction Structure
Defines whether the deal is an asset purchase, stock purchase, or MSO structure, and explains what is being acquired — clinical equipment, patient records, payer contracts, goodwill, the facility lease, and non-clinical business assets. This section is especially important in pain management because DEA registration and certain payer contracts cannot be transferred in an asset purchase and must be re-credentialed or newly applied for.
Example Language
The proposed transaction is structured as an asset purchase ('Transaction'), in which Buyer will acquire all tangible and intangible assets of the Practice used in the operation of the pain management clinic, including but not limited to: medical equipment and procedure suite assets, patient records (subject to HIPAA requirements), the assignable portion of payer contracts, trade name and goodwill, office furniture and fixtures, and the leasehold interest in the premises located at [Address]. Excluded from the purchase are cash, accounts receivable generated prior to the Closing Date, and liabilities not expressly assumed. The parties acknowledge that Buyer will independently apply for a new DEA registration and will work cooperatively with Seller to notify payers and initiate re-credentialing as promptly as practicable following execution of a definitive agreement.
💡 Asset purchases are the most common structure for SBA-financed pain clinic acquisitions and provide the buyer with a step-up in tax basis and protection from unknown predecessor liabilities. However, sellers often prefer stock purchases to achieve capital gains treatment on the full proceeds and to avoid re-credentialing delays. Stock purchases carry the risk that the buyer inherits legacy DEA compliance issues, billing audit exposure, and historical malpractice claims — making robust representations and indemnification provisions essential. MSO structures add complexity but may be legally required; in that case, the LOI should describe the dual-entity framework (MSO for management, PC for clinical services) and confirm that the physician-owner will execute a long-term management services agreement.
3. Purchase Price and Valuation Basis
States the proposed purchase price, the EBITDA or seller's discretionary earnings (SDE) basis used to derive it, and the implied valuation multiple. Pain management clinics in the lower middle market typically trade at 3.5x–6x EBITDA depending on payer mix quality, procedure revenue concentration, physician dependency, and regulatory history.
Example Language
Based on Buyer's preliminary review of the Practice's financial statements for the trailing twelve months ended [Date], Buyer proposes a total purchase price of $[Amount] ('Purchase Price'), representing approximately [X.Xx] times the Practice's normalized EBITDA of $[Amount]. The Purchase Price is subject to adjustment following completion of financial due diligence, quality of earnings analysis, and revenue cycle management review. Buyer reserves the right to adjust the Purchase Price if due diligence reveals material undisclosed liabilities, billing compliance issues, payer contract terminations, or significant changes in physician staffing prior to Closing.
💡 Pain management clinic valuations are highly sensitive to payer mix — practices with 60%+ commercial insurance revenue command multiples at the higher end of the 3.5x–6x range, while Medicare/Medicaid-heavy practices face compression due to reimbursement rate risk and CMS audit exposure. Normalize EBITDA carefully: physician owner compensation should be recast to market-rate replacement cost, which for a board-certified pain management physician is typically $350,000–$500,000 per year depending on the region. Exclude one-time legal or consulting fees, personal expenses run through the practice, and any revenue from non-recurring procedures. If the seller disputes the normalized EBITDA, propose a mutually agreed-upon quality of earnings (QoE) engagement with a third-party accounting firm as a condition of moving to a definitive agreement.
4. Payment Terms and Deal Structure
Describes how the purchase price will be funded — typically a combination of SBA 7(a) loan proceeds, seller financing, and buyer equity — and any earnout or contingent payment provisions tied to post-close performance metrics such as physician retention, revenue, or EBITDA.
Example Language
The Purchase Price shall be paid as follows: (a) $[Amount] in cash at Closing, funded through proceeds of an SBA 7(a) loan for which Buyer is seeking lender approval; (b) $[Amount] in the form of a seller note payable over [24–60] months at [6–8]% per annum, subordinated to the SBA lender; and (c) up to $[Amount] in contingent earnout payments payable over [12–24] months following Closing, based on the Practice achieving no less than [90]% of its trailing twelve-month net collected revenue, contingent upon the continued employment of [Physician Name, MD] as the Practice's medical director. Seller financing shall be evidenced by a promissory note and secured by a second lien on the acquired assets, subject to SBA lender standby requirements.
💡 SBA 7(a) loans are the dominant financing mechanism for pain clinic acquisitions under $5M and require the seller to carry a standby note (typically 10–15% of purchase price) with limited payment rights during the standby period. Earnouts are common in physician-dependent practices but are a frequent source of post-close disputes — define the earnout metric precisely (net collected revenue, not billed revenue), specify whether the earnout resets if key physicians are terminated without cause by the buyer, and establish a clear audit right for the seller. If the selling physician is also receiving a post-close employment agreement, ensure the earnout is not inadvertently structured as disguised compensation that could trigger IRS scrutiny or SBA rule violations.
5. Exclusivity and No-Shop Period
Grants the buyer an exclusive negotiation period during which the seller agrees not to solicit, entertain, or accept offers from other potential acquirers. Given the due diligence complexity of pain management acquisitions — including DEA compliance review, revenue cycle audits, and payer contract analysis — buyers should request 60–90 days of exclusivity.
Example Language
In consideration of Buyer's commitment to devote substantial time and resources to due diligence and transaction documentation, Seller agrees that for a period of [75] days following the date of Seller's execution of this LOI ('Exclusivity Period'), Seller shall not, and shall cause its representatives and advisors not to, directly or indirectly solicit, initiate, encourage, or participate in discussions or negotiations with any third party regarding the acquisition of all or any material portion of the Practice or its assets. Seller shall promptly notify Buyer if any unsolicited acquisition inquiry is received during the Exclusivity Period. The Exclusivity Period shall automatically extend by [15] days if the parties are engaged in active good-faith negotiations toward a definitive agreement at the time of expiration.
💡 Sellers with multiple interested parties will resist long exclusivity periods; buyers should be prepared to justify 60–90 days by pointing to the complexity of DEA compliance review, payer contract assignability analysis, and SBA lender underwriting timelines — all of which genuinely require more time in healthcare transactions than in standard business acquisitions. Offer to share a detailed due diligence timeline at LOI signing to demonstrate seriousness and organizational capability. If the seller insists on a shorter window (30–45 days), consider whether you can compress the due diligence workplan or whether a shorter period creates unacceptable risk of incomplete findings.
6. Due Diligence Conditions and Access
Outlines the scope of due diligence the buyer requires, the information and access the seller must provide, and the timeline for completing the review. Pain management-specific due diligence is more extensive than most lower middle market acquisitions and must address DEA compliance, PDMP adherence, payer contract review, revenue cycle quality, malpractice history, and physician employment agreements.
Example Language
Buyer's obligation to proceed to a definitive purchase agreement is contingent upon satisfactory completion of due diligence, including but not limited to: (a) review of three (3) years of CPA-reviewed or audited financial statements and tax returns; (b) DEA registration status verification and review of any prior DEA audits, investigations, or administrative actions; (c) review of opioid prescribing patterns and compliance with applicable state Prescription Drug Monitoring Program (PDMP) requirements; (d) payer contract review including current reimbursement rates, assignability provisions, and any pending audits or recoupment demands from Medicare, Medicaid, or commercial carriers; (e) revenue cycle management analysis including coding accuracy, denial rates, days in accounts receivable, and billing compliance; (f) review of all physician and clinical staff employment agreements, non-compete provisions, and compensation arrangements; and (g) review of malpractice claims history and current liability insurance coverage. Seller agrees to provide Buyer with reasonable access to personnel, records, and premises during normal business hours upon reasonable advance notice.
💡 DEA compliance and opioid prescribing history are the highest-risk due diligence items in any pain management acquisition — a history of DEA audits, prescribing outside standard-of-care guidelines, or unanticipated patterns in PDMP data can kill a deal or dramatically reduce purchase price. Engage a healthcare compliance attorney with DEA experience to conduct this review independently of the financial due diligence. Revenue cycle management quality is the second most common source of purchase price adjustments — undercoding, high denial rates, and aged AR (over 120 days) are pervasive in physician-run practices. A revenue cycle audit by a specialized medical billing consultant is a worthwhile investment even for smaller transactions.
7. Representations and Warranties Preview
Outlines the categories of representations and warranties the seller will be required to make in the definitive purchase agreement. Including a preview in the LOI signals the buyer's expectations and helps the seller's counsel begin preparing disclosure schedules early, reducing delays at the definitive agreement stage.
Example Language
The definitive purchase agreement will include customary representations and warranties from Seller covering, among other matters: (a) legal authority and ownership of the Practice; (b) accuracy of financial statements and absence of undisclosed liabilities; (c) compliance with all applicable federal and state healthcare laws including the Anti-Kickback Statute, Stark Law, False Claims Act, and HIPAA; (d) DEA registration status and absence of any pending or threatened DEA, OIG, or state medical board investigations or sanctions; (e) accuracy of billing and coding practices and absence of any outstanding payer audits, recoupment demands, or overpayment notifications; (f) validity and assignability of material payer contracts; (g) status of physician licensure and board certifications; and (h) absence of material malpractice claims or professional liability actions not disclosed in writing to Buyer prior to Closing.
💡 Sellers frequently push back on the breadth of healthcare-specific reps and warranties, particularly around billing compliance and DEA history, citing inability to warrant conduct from prior years. Buyers should hold firm on these provisions — they are specifically designed to allocate known and unknown regulatory risk. Consider requesting a compliance representation period dating back at least five (5) years to capture potential CMS look-back audit exposure. For deals involving seller financing, the seller's willingness to make strong reps and warranties also signals confidence in the practice's clean history, which is itself a meaningful deal signal.
8. Physician Transition and Employment Terms
Addresses the post-close role of the selling physician, whether as a salaried employee, independent contractor, or medical director, and specifies the minimum transition period the buyer requires to protect patient relationships and ensure clinical continuity. This is one of the most deal-critical sections in a pain management LOI.
Example Language
As a condition to Closing, Seller (or the principal physician(s) of the Practice) shall enter into an employment or professional services agreement with Buyer (or the Buyer-affiliated physician entity) for a minimum period of [24] months post-Closing ('Transition Period'), serving as [Medical Director / Attending Physician] on terms mutually acceptable to the parties. During the Transition Period, Seller shall actively support the transition of patient relationships to employed or newly recruited physicians, participate in payer re-credentialing efforts, and maintain all required DEA registrations and state medical licenses necessary to operate the Practice. Post-Transition Period non-compete and non-solicitation provisions applicable to [Seller Physician Name, MD] shall cover a radius of [X] miles from the Practice's primary location and a term of [2–3] years, subject to applicable state law enforceability standards.
💡 Physician retention post-close is the single most important operational risk in a pain management acquisition. Buyers should insist on a minimum 24-month employment agreement for the primary selling physician, with compensation at or near market rate to reduce the risk of early departure. Non-compete enforceability varies dramatically by state — California essentially prohibits them for physicians, while Texas and Florida enforce them with restrictions. Engage local healthcare counsel to confirm what is enforceable before including non-compete terms in the LOI. If the earnout is tied to physician retention, ensure the employment agreement and earnout provisions are cross-referenced so that a buyout of the employment agreement by the physician does not inadvertently trigger full earnout payment without corresponding revenue performance.
9. Conditions to Closing
Lists the specific conditions that must be satisfied before the transaction can close, including regulatory approvals, payer credentialing milestones, DEA registration, landlord consent to lease assignment, and completion of SBA lender underwriting. Pain management closings routinely take 4–9 months due to credentialing timelines.
Example Language
The obligations of the parties to consummate the Transaction are subject to satisfaction of the following conditions prior to or at Closing: (a) Buyer's receipt of SBA 7(a) loan approval and funding commitment in an amount sufficient to fund the cash portion of the Purchase Price; (b) Buyer's (or Buyer's designated physician's) receipt of all required DEA registrations and state controlled substance permits necessary to prescribe and administer medications at the Practice's location(s); (c) completion of payer re-credentialing for at least [80]% of the Practice's top payers by gross revenue, or receipt of written confirmation from such payers that assignment of existing contracts will be honored; (d) receipt of landlord consent to the assignment of the Practice's facility lease, or execution of a new lease on terms acceptable to Buyer; (e) execution of the physician employment or professional services agreement referenced in Section 8; and (f) absence of any material adverse change in the Practice's business, financial condition, regulatory status, or payer relationships between the date of this LOI and the Closing Date.
💡 Payer credentialing is the most common cause of delayed closings in pain management acquisitions. Medicare and Medicaid enrollment can take 90–180 days; commercial payers vary widely. To avoid a scenario where the buyer cannot bill insurance on day one, consider a transition services agreement (TSA) under which the seller's entity continues to bill payers on behalf of the buyer for a defined period post-close, with all collections remitted to the buyer. This arrangement requires careful HIPAA and Anti-Kickback Statute compliance review. SBA lenders also have specific requirements around healthcare business acquisitions, including confirmation of DEA registration and payer contracts, so engage your lender early in the process to align their underwriting timeline with the closing conditions.
10. Confidentiality and Non-Binding Nature
Confirms that the LOI is non-binding except for specific provisions (exclusivity, confidentiality, and governing law) and that both parties acknowledge that no binding transaction exists until a definitive purchase agreement is executed. Reinforces the confidentiality obligations from any separately executed NDA.
Example Language
This LOI is intended to summarize the principal terms of the proposed Transaction for discussion purposes only. Except for the provisions of Sections 5 (Exclusivity), 10 (Confidentiality), and 11 (Governing Law), which are intended to be binding upon the parties, this LOI does not constitute a binding agreement and shall not create any legal obligation on the part of either party to consummate the Transaction. A binding obligation to proceed with the Transaction will arise only upon execution of a definitive purchase agreement satisfactory to both parties and their respective legal counsel. All information exchanged by the parties in connection with this LOI and the proposed Transaction shall be maintained in strict confidence consistent with the terms of the Mutual Non-Disclosure Agreement executed by the parties on [Date].
💡 The non-binding nature of the LOI is standard and expected, but sellers should ensure that confidentiality provisions are explicitly binding and extend to any employees, advisors, or financing sources who receive access to practice information during due diligence. For pain management practices, confidentiality is especially important given the sensitivity of DEA prescribing data, patient census information, and payer contract terms. Buyers should confirm that their SBA lender, QoE accountants, and healthcare compliance consultants have each executed appropriate confidentiality agreements before receiving any materials from the seller.
Earnout Structure and Physician Retention Linkage
Earnouts tied to physician retention and post-close revenue performance are standard in pain management acquisitions but are a frequent source of post-close disputes. Buyers should define the earnout metric using net collected revenue (not gross billed charges) over a 12–24 month period, specify whether the earnout is pro-rated if the selling physician is terminated without cause by the buyer, and establish a clear third-party audit right for the seller. Sellers should negotiate for automatic earnout payment if the buyer fails to provide agreed staffing or operational support that materially impairs revenue performance.
DEA Registration and Controlled Substance Transition
DEA registrations are non-transferable and cannot be assigned in an asset purchase — the buyer or their designated physician must apply for a new registration, which can take 4–12 weeks. The LOI should address how controlled substance inventory will be handled at closing (typically transferred under a DEA-approved procedure or disposed of before close), confirm that the seller's DEA registration remains in good standing through closing, and specify that any pending DEA inquiries constitute a closing condition failure. This provision protects the buyer from inheriting a practice whose DEA status is compromised.
Payer Contract Assignment and Re-Credentialing Threshold
Most payer contracts prohibit assignment without consent, and Medicare enrollment must be re-established by the buyer independently. The LOI should specify a minimum percentage of payer contracts (by gross revenue) that must be assignable or successfully re-credentialed before the buyer is obligated to close — typically 75–85% of the top payers by revenue. Include a transition services agreement provision allowing the seller to bill on the buyer's behalf during any credentialing gap period, with explicit Anti-Kickback Statute compliance review by healthcare counsel.
Representations and Warranties Survival Period and Indemnification Caps
Sellers will push for a short survival period (12–18 months) and a low indemnification cap (equal to a portion of the purchase price) on reps and warranties. Buyers should push for healthcare-specific reps — particularly those covering DEA compliance, billing and coding accuracy, and Anti-Kickback/Stark Law compliance — to survive for at least 36 months given the look-back periods used in government healthcare audits. An indemnification cap of 100% of the purchase price is appropriate for fundamental reps and fraud; 25–50% for general reps. Consider representation and warranty insurance for transactions over $2M to bridge the gap between buyer and seller risk tolerance.
Non-Compete Scope, Radius, and State Law Enforceability
Non-compete agreements for physicians are governed by state law and range from fully enforceable (Texas, Florida) to effectively unenforceable (California). The LOI should specify the proposed non-compete radius (typically 10–25 miles depending on market density), term (2–3 years), and scope (pain management and closely related specialties). Sellers in states with weak non-compete enforcement should be prepared to offer non-solicitation of patients and referral sources as an alternative protection for the buyer. Buyers should not rely on a non-compete alone to protect the value of the acquisition — transition earnouts and physician employment agreements are more practically effective retention tools.
Purchase Price Adjustment Mechanism for Revenue Cycle Findings
Revenue cycle management quality in physician-owned pain clinics is frequently worse than what informal financial reviews suggest, with undercoding, high denial rates, and aged accounts receivable creating a significant gap between billed and collected revenue. The LOI should include an explicit purchase price adjustment mechanism triggered if the revenue cycle due diligence reveals that trailing twelve-month net collected revenue is materially below the figures represented by the seller. Define materiality thresholds (e.g., a variance exceeding 10% of trailing collected revenue) and specify whether adjustments reduce the total purchase price, the seller note, or both.
Find Pain Management Clinic Businesses to Acquire
Enough information to write a strong LOI on day one — free to join.
Yes — this is one of the most important deal structure issues to resolve before signing the LOI, not after. Most states prohibit non-physician entities from directly owning or operating a medical practice under corporate practice of medicine (CPOM) doctrines. In those states (which include California, Texas, New York, and many others), a non-physician buyer must use a Management Services Organization (MSO) structure, in which a non-physician entity acquires all non-clinical business assets and contracts with a separately owned physician professional corporation (PC) under a long-term management services agreement. The LOI should explicitly identify the proposed structure — direct asset purchase or MSO/PC arrangement — so that both parties and their counsel can begin drafting definitive documents on the correct legal framework from day one. Failing to address this in the LOI is one of the most common and costly mistakes in pain management acquisitions.
For pain management clinic acquisitions, 60–90 days of exclusivity is appropriate and justifiable given the complexity of the due diligence required. DEA compliance review, revenue cycle management audits, payer contract analysis, and SBA lender underwriting each take meaningful time when done properly. A 30-day exclusivity period — common in simpler business acquisitions — is rarely sufficient and often results in buyers rushing diligence, missing critical regulatory issues, or losing SBA lender approval due to incomplete documentation. If the seller resists a 75–90 day window, offer to share a detailed due diligence timeline at LOI signing with specific milestone dates so the seller can see the structure of your process and hold you accountable to it.
DEA registrations for Schedule II controlled substances are non-transferable — they cannot be assigned from the seller to the buyer in an asset purchase. This means the buyer, or a physician employed by the buyer, must apply for a new DEA registration before the practice can continue prescribing opioids, stimulants, and other Schedule II medications. New DEA registrations can take 60–120 days or longer in some states, creating a gap in prescribing capability that directly impacts revenue. The LOI should condition closing on the buyer's receipt of all required DEA registrations (or on a transition arrangement agreed upon with DEA counsel), and should address how existing controlled substance inventory will be handled at closing — typically either transferred under specific DEA protocols or properly disposed of before the closing date. This issue should be addressed proactively in the LOI and managed closely throughout the deal process.
Goodwill in a pain management clinic represents the practice's patient base, referral network, brand reputation, and going-concern value — and it typically constitutes 40–70% of total enterprise value in these transactions. SBA 7(a) loans can and do finance goodwill in healthcare acquisitions, but lenders scrutinize it carefully in physician-dependent practices because goodwill is at risk if the selling physician departs. Lenders typically require the selling physician to sign a meaningful post-close employment agreement (usually 24+ months) and may require a portion of the purchase price to be held in seller financing subordinated to the SBA loan as evidence that the seller has confidence in the continuity of the business. A quality of earnings analysis that documents recurring revenue streams, the referral network's breadth beyond a single physician, and the strength of interventional procedure revenue (which is less physician-dependent than medication management alone) will materially strengthen the SBA lender's comfort with financing intangible value.
Several opioid-related findings can significantly impact or kill a pain management acquisition. The most serious include: an active or recently closed DEA investigation or administrative action; a state medical board sanction, probation, or license restriction related to prescribing practices; outstanding CMS or commercial payer audit demands related to opioid billing; a pattern of high-dose, long-term opioid prescribing significantly outside standard-of-care benchmarks without documented clinical justification; and a history of prescribing to patients with known diversion or abuse patterns documented in PDMP data. Less severe but price-reducing issues include: elevated opioid prescribing ratios relative to peers that create future audit risk even without prior findings; outdated or incomplete PDMP compliance documentation; and absence of documented urine drug testing protocols. Buyers should engage a healthcare compliance attorney with DEA experience to conduct a dedicated prescribing audit as part of due diligence — this is not an area where general business due diligence frameworks are adequate.
Yes — pain management clinics are SBA-eligible businesses, and SBA 7(a) loans are the most common financing mechanism for acquisitions in the $1M–$5M revenue range. Typical deal structures involve the SBA loan covering 70–80% of the purchase price, with the remaining 20–30% funded through a combination of buyer equity and seller financing (the seller note is typically required to be on standby for 24 months per SBA guidelines). SBA lenders underwriting pain management acquisitions pay close attention to DEA registration continuity, payer contract assignability, physician retention via employment agreement, and post-close revenue sustainability. Buyers should engage an SBA lender with healthcare industry experience early in the process — before LOI signing if possible — to confirm lender appetite for the specific practice and identify any documentation requirements that should be addressed in the LOI's due diligence and closing conditions sections.
More Pain Management Clinic Guides
More LOI Templates
Get enough diligence data to write a confident LOI from day one.
Create your free accountNo credit card required
For Buyers
For Sellers